Condition: HER2-positive Breast Cancer · LMD · Sponsor: Sunnybrook Health Sciences Centre
The proposed study will evaluate the safety and efficacy of XRT followed by systemic therapy among patients with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer and LMD
This description comes directly from the study's public registry record.
CLIMB-LMD Project Manager · 437-247-2617 · CLIMB-LMD@sunnybrook.ca
Dr. Katarzyna Jerzak · 437-247-2617 · katarzyna.jerzak@sunnybrook.ca
Always discuss trial participation with your own doctor first.
| The Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06016387